Recent advances in CAR-T cells therapy for colorectal cancer

Qin, Xiaoxia; Wu, Fengjiao; Chen, Chang; Li, Qi

doi:10.3389/fimmu.2022.904137

Cited by 16 publications

(6 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the rapid development of CRISPR-Cas9 technology, the use of chimeric antigen receptor-T (CAR-T) cells is the other strategy to target specific tumor-associated antigens[ 20 ]. Although a total of 25 CAR-T cell clinical trials for CRC are ongoing as of 2022[ 21 ], the application of CAR-T cell therapy to CRC faces a challenge because of the limited infiltration of CAR-T cells to the local tumor tissues, as discussed in detail[ 20 ]. This lack of infiltration is a major challenge in the application of CAR-T therapy to solid tumors in general.…”

Section: Long Way To Developing Effective Immunotherapy For Crcmentioning

confidence: 99%

Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management

Kita,

Burdowski

2024

World J Gastroenterol

View full text Add to dashboard Cite

Colorectal cancer (CRC) has remained the second and the third leading cause of cancer-related death worldwide and in the United States, respectively. Although significant improvement in overall survival has been achieved, death in adult populations under the age of 55 appears to have increased in the past decades. Although new classes of therapeutic strategies such as immunotherapy have emerged, their application is very limited in CRC so far. Microtubule (MT) inhibitors such as taxanes, are not generally successful in CRC. There may be some way to make MT inhibitors work effectively in CRC. One potential advantage that we can take to treat CRC may be the combination of optical techniques coupled to an endoscope or other fiber optics-based devices. A combination of optical devices and photo-activatable drugs may allow us to locally target advanced CRC cells with highly potent MT-targeting drugs. In this Editorial review, we would like to discuss the potential of optogenetic approaches in CRC management.

show abstract

Section: Long Way To Developing Effective Immunotherapy For Crcmentioning

confidence: 99%

Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management

Kita,

Burdowski

2024

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Notably, all data regarding clinical trials of CAR-T therapy for CRC were collected from ClinicalTrials.gov; thus, only ClinicalTrials.gov-registered trials were included. Human epidermal growth factor receptor 2 (HER2), epithelial cell adhesion molecule (EpCAM), and mesothelin (MSLN) antigens along with NK group 2 member D ligand (NKG2DL), MUC-1, and CD133 have been licensed for use in clinical trials ( Table 2 ) because they are among the most overexpressed antigens in patients with CRC ( 107 ). Figure 2B provides a concise depiction of the T cell engineering process, illustrating the formation of CAR and TCR-T cells.…”

Section: Gene-modified T Cell Therapymentioning

confidence: 99%

Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy

Shebbo,

Binothman,

Darwaish

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common cancer globally and presents a significant challenge owing to its high mortality rate and the limitations of traditional treatment options such as surgery, radiotherapy, and chemotherapy. While these treatments are foundational, they are often poorly effective owing to tumor resistance. Immunotherapy is a groundbreaking alternative that has recently emerged and offers new hope for success by exploiting the body’s own immune system. This article aims to provide an extensive review of clinical trials evaluating the efficacy of various immunotherapies, including CRC vaccines, chimeric antigen receptor T-cell therapies, and immune checkpoint inhibitors. We also discuss combining CRC vaccines with monoclonal antibodies, delve into preclinical studies of novel cancer vaccines, and assess the impact of these treatment methods on patient outcomes. This review seeks to provide a deeper understanding of the current state of CRC treatment by evaluating innovative treatments and their potential to redefine the prognosis of patients with CRC.

show abstract

“…Tai pasiekiama į T limfocitus įterpiant specialius receptorius (CAR -chimerozinis antigenų receptorius), kurie leidžia labiau orientuotis į vėžines ląsteles ir jas atakuoti. Minėtas metodas plačiai tiriamas įvairiems vėžio tipams gydyti, įskaitant kolorektalinį vėžį [46][47][48].…”

Section: Storosios žArnos Vėžio Gydymasunclassified

Colon Cancer Genetic and Epigenetic Changes, Etiopathogenesis, Risk Factors, Treatment: Literature Review

Ūbaitė,

Remeikaitė,

Žilinskas

2024

View full text Add to dashboard Cite

Background. Colorectal cancer (CRC) ranks as the third leading cause of cancerrelated mortality worldwide. Recent years have witnessed an increase in the incidence of CRC. The main reasons are ageing population, increased consumption of processed food, obesity, genetic predispositions. Aim. To review the latest scientific developments and novel factors on the epidemiology, etiology, pathogenesis of colon cancer, focusing on the influence of genetics and epigenetics, risk factors, and the advancement of prevention and treatment methods. Material and methods. The research method is a literature review. Publications were searched in the PubMed database using the following keywords and their combinations in English: colon cancer, colorectal cancer, management, prevalence, causes, risk factors, genetic and epigenetic changes. Selection criteria for publications: scientific articles in English relevant to the research topic and 90% of articles published in the last 10 years (2014–2024). Results. Using theoretical analysis methods, 72 publications were selected that met the inclusion criteria. Our findings emphasize the central role of genetic mutations (particularly in APC, TP53, KRAS and MMR) and epigenetic alterations, such as DNA methylation and histone modification, in the pathogenesis of colorectal cancer. These genetic and epigenetic factors drive the progression from benign polyps to malignant carcinomas, with environmental, lifestyle, and chronic disease factors also playing a critical role. In particular, diet, physical inactivity, smoking and alcohol significantly increase risk, especially in men and those over 50. Innovations such as CRISPR/Cas9 offer new avenues for targeted treatments, while advances in vaccines and liquid biopsy techniques are improving immune response activation and disease monitoring. In addition, diets rich in fiber, antioxidants and healthy fats, as well as the use of probiotics and NSAIDs, are key to reducing cancer risk through their anti-inflammatory effects and promoting gut health. Conclussions. This review highlights the significant impact of genetic and epigenetic factors on colorectal cancer (CRC) development, in addition to the role of lifestyle and environmental exposures. It highlights the potential of CRISPR/Cas9, immunotherapies, and liquid biopsies in pioneering personalized CRC treatments and early detection. Advances in prevention and technology promise a new era of personalized, effective CRC management strategies.

show abstract

Recent advances in CAR-T cells therapy for colorectal cancer

Cited by 16 publications

References 113 publications

Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management

Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management

Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy

Colon Cancer Genetic and Epigenetic Changes, Etiopathogenesis, Risk Factors, Treatment: Literature Review

Contact Info

Product

Resources

About